XP0 Stock Overview A neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. More details
Rewards Risk Analysis See All Risk Checks Capture your thoughts, links and company narrative
Xenon Pharmaceuticals Inc. Competitors Price History & Performance
Summary of share price highs, lows and changes for Xenon Pharmaceuticals Historical stock prices Current Share Price US$37.60 52 Week High US$46.60 52 Week Low US$33.40 Beta 1.19 1 Month Change -6.00% 3 Month Change 4.44% 1 Year Change -6.93% 3 Year Change 38.24% 5 Year Change 166.67% Change since IPO 216.97%
Recent News & Updates
Xenon Pharmaceuticals Inc. to Showcase New Long-Term Azetukalner Data at AES 2024 Nov 26
Xenon Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Now 22% overvalued after recent price rise Oct 21
Xenon Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Xenon Pharmaceuticals Inc. Presents Data from Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder At the American Society of Clinical Psychopharmacology 2024 Annual Meeting May 29
Xenon Pharmaceuticals Inc. to Report Q1, 2024 Results on May 09, 2024 May 03 See more updates
Xenon Pharmaceuticals Inc. to Showcase New Long-Term Azetukalner Data at AES 2024 Nov 26
Xenon Pharmaceuticals Inc. to Report Q3, 2024 Results on Nov 12, 2024 Nov 06
Now 22% overvalued after recent price rise Oct 21
Xenon Pharmaceuticals Inc. to Report Q2, 2024 Results on Aug 08, 2024 Aug 02
Xenon Pharmaceuticals Inc. Presents Data from Phase 2 X-Nova Clinical Trial of Azetukalner in Major Depressive Disorder At the American Society of Clinical Psychopharmacology 2024 Annual Meeting May 29
Xenon Pharmaceuticals Inc. to Report Q1, 2024 Results on May 09, 2024 May 03
Independent Director recently sold €550k worth of stock Mar 10
Xenon Pharmaceuticals Inc., Annual General Meeting, Jun 04, 2024 Mar 09
Xenon Pharmaceuticals Inc. to Report Q4, 2023 Results on Feb 29, 2024 Feb 23
Independent Director recently sold €284k worth of stock Dec 18 Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $300.000013 million. Dec 01
Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $300.000013 million.
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder (Mdd) Nov 29
New minor risk - Share price stability Nov 29
Xenon Pharmaceuticals Announces Topline Results from Phase 2 Proof-Of-Concept X-Nova Clinical Trial of Xen1101 in Major Depressive Disorder (Mdd) Nov 28
Xenon Pharmaceuticals Inc. to Report Q3, 2023 Results on Nov 08, 2023 Nov 02
Xenon Pharmaceuticals Announces Publication of Results from Xen1101 Phase 2B "X-Tole" Clinical Trial in Peer-Reviewed Journal Article in Jama Neurology Oct 10
Xenon Pharmaceuticals Inc. Showcases XEN1101 Epilepsy Program at 35th International Epilepsy Congress Sep 05
High number of new directors Sep 01
Lead Independent Director recently sold €893k worth of stock Aug 25
First half 2023 earnings released: US$1.38 loss per share (vs US$0.87 loss in 1H 2022) Aug 10
Xenon Pharmaceuticals Inc. Announces Board Appointments Aug 09
Xenon Pharmaceuticals Inc. to Report Q2, 2023 Results on Aug 09, 2023 Aug 03
Chairman of the Board recently sold €3.9m worth of stock Jun 05
First quarter 2023 earnings released: US$0.66 loss per share (vs US$0.37 loss in 1Q 2022) May 10
Full year 2022 earnings released: US$2.06 loss per share (vs US$1.50 loss in FY 2021) Mar 04
Xenon Pharmaceuticals Inc. Provides Updates on Proprietary Neurology Pipeline Programs at the Annual Meeting of the American Epilepsy Society (AES 2022) Dec 03
Independent Director recently sold €68k worth of stock Nov 30
Third quarter 2022 earnings released: US$0.57 loss per share (vs US$0.36 loss in 3Q 2021) Nov 10
Now 23% undervalued after recent price drop Nov 08
Xenon Pharmaceuticals Inc. Announces Appointment of Andrea Difabio as Chief Legal Officer and Corporate Secretary Nov 08
Xenon Pharmaceuticals Inc. Announces Launch of XEN1101 Phase 3 Program with Initiation of X TOLE2 Clinical Trial in Patients with Focal Onset Seizures Nov 04 Xenon Pharmaceuticals Inc. to Report Q3, 2022 Results on Nov 08, 2022 Nov 02
Chairman of the Board recently sold €6.7m worth of stock Aug 17
Second quarter 2022 earnings released: US$0.59 loss per share (vs US$0.53 loss in 2Q 2021) Aug 11
Xenon Pharmaceuticals Inc. to Report Q2, 2022 Results on Aug 09, 2022 Aug 03
Xenon Pharmaceuticals Provides Update on Additional Positive Data from the XEN1101 Program Jun 24
Xenon Pharmaceuticals Announces Positive Outcome of End-of-Phase 2 Meeting with the FDA Jun 22
Xenon Pharmaceuticals Inc. Announces Michael Hayden Will Not Stand for Re-Election as Member of Board Jun 04
First quarter 2022 earnings released: US$0.36 loss per share (vs US$0.38 loss in 1Q 2021) May 12 Xenon Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial to Evaluate XEN1101 as Treatment for Major Depressive Disorder
Executive Chairman recently sold €674k worth of stock Mar 10
Full year 2021 earnings: EPS in line with expectations, revenues disappoint Mar 03
Xenon Pharmaceuticals Inc. to Report Fiscal Year 2021 Results on Mar 01, 2022 Feb 24
Xenon Pharmaceuticals Inc. announced that it expects to receive $8.249999 million in funding from Neurocrine Biosciences, Inc. Jan 13
Chief Commercial Officer recently bought €87k worth of stock Dec 08
Xenon Pharmaceuticals Presents Additional Positive Data from Phase 2b ‘X-TOLE’ Clinical Trial at the Annual Meeting of the American Epilepsy Society Dec 05
Executive Chairman recently sold €482k worth of stock Nov 19
Third quarter 2021 earnings released: US$0.37 loss per share (vs US$0.25 loss in 3Q 2020) Nov 11
Xenon Pharmaceuticals Inc. announced that it expects to receive $5.499994 million in funding from Neurocrine Biosciences, Inc. Sep 09
Second quarter 2021 earnings released: US$0.50 loss per share (vs US$0.005 loss in 2Q 2020) Aug 12
High number of new directors Aug 01
Independent Chairman Michael Tarnow has left the company Jun 11
Independent Director Clarissa Desjardins has left the company Jun 09
Independent Director Frank Holler has left the company Jun 08
First quarter 2021 earnings released: US$0.42 loss per share (vs US$0.22 loss in 1Q 2020) May 13
Xenon Pharmaceuticals Reports Topline Data from XEN1101 Phase 2B 'X-TOLE' Clinical Trial Anticipate by End of Third Quarter of 2021 May 12
Chief Medical Officer has left the company Apr 25
Xenon Pharmaceuticals Announces Collaboration with Researchers At Icahn School of Medicine at Mount Sinai to Conduct a Phase 2 Study of Xen1101 for the Treatment of Major Depressive Disorder Mar 10 Xenon Pharmaceuticals Inc. Provides a Corporate Update
Full year 2020 earnings released: US$0.81 loss per share (vs US$1.54 loss in FY 2019) Mar 02
Revenue beats expectations Mar 02
New 90-day high: €15.60 Feb 26 Xenon Pharmaceuticals Inc. to Report Fiscal Year 2020 Results on Mar 01, 2021
New 90-day high: €13.90 Feb 04
Xenon Pharmaceuticals Inc. and Neurocrine Biosciences, Inc. Enter into Amendment to the License and Collaboration Agreement Jan 16 Xenon Pharmaceuticals Inc. Outlines Key Milestone Opportunities in 2021
New 90-day high: €12.20 Jan 09
New 90-day high: €11.30 Dec 22
Revenue misses expectations Nov 07
Xenon Pharmaceuticals Inc. Announces Board Changes Nov 06
Xenon Pharmaceuticals Inc. to Report Q3, 2020 Results on Nov 05, 2020 Nov 05
New 90-day low: €8.80 Oct 21 Neurocrine Biosciences and Xenon Pharmaceuticals Provide Regulatory Update on Ongoing Collaboration to Develop First-In-Class Treatment for Epilepsy
Earnings released Aug 07
Xenon Pharmaceuticals Inc. to Report Q2, 2020 Results on Aug 06, 2020 Jul 31
New 90-day low - €9.95 Jul 30
Xenon Pharmaceuticals Inc. has completed a Follow-on Equity Offering in the amount of $50 million. Jul 09 Shareholder Returns XP0 DE Biotechs DE Market 7D 1.6% 2.3% 0.3% 1Y -6.9% -11.7% 8.4%
See full shareholder returns
Return vs Market: XP0 underperformed the German Market which returned 8.4% over the past year.
Price Volatility Is XP0's price volatile compared to industry and market? XP0 volatility XP0 Average Weekly Movement 5.7% Biotechs Industry Average Movement 7.6% Market Average Movement 4.8% 10% most volatile stocks in DE Market 11.8% 10% least volatile stocks in DE Market 2.4%
Stable Share Price: XP0 has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: XP0's weekly volatility (6%) has been stable over the past year.
About the Company Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy.
Show more Xenon Pharmaceuticals Inc. Fundamentals Summary How do Xenon Pharmaceuticals's earnings and revenue compare to its market cap? XP0 fundamental statistics Market cap €2.91b Earnings (TTM ) -€207.93m Revenue (TTM ) n/a
Earnings & Revenue Key profitability statistics from the latest earnings report (TTM) XP0 income statement (TTM ) Revenue US$0 Cost of Revenue US$192.00m Gross Profit -US$192.00m Other Expenses US$21.39m Earnings -US$213.39m
Company Analysis and Financial Data Status Data Last Updated (UTC time) Company Analysis 2025/01/02 02:41 End of Day Share Price 2025/01/02 00:00 Earnings 2024/09/30 Annual Earnings 2023/12/31
Data Sources The data used in our company analysis is from S&P Global Market Intelligence LLC . The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
Package Data Timeframe Example US Source * Company Financials 10 years Income statement Cash flow statement Balance sheet Analyst Consensus Estimates +3 years Forecast financials Analyst price targets Market Prices 30 years Stock prices Dividends, Splits and Actions Ownership 10 years Top shareholders Insider trading Management 10 years Leadership team Board of directors Key Developments 10 years
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here .
Analysis Model and Snowflake Details of the analysis model used to generate this report is available on our Github page , we also have guides on how to use our reports and tutorials on Youtube .
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources Xenon Pharmaceuticals Inc. is covered by 24 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
Analyst Institution Brian Skorney Baird Jason Matthew Gerberry BofA Global Research John Newman Canaccord Genuity
Show 21 more analysts 
